HTR2A gene variation is involved in antidepressant treatment response

Susanne Lucae; Marcus Ising; Sonja Horstmann; Bernhard T Baune; Volker Arolt; Bertram Müller-Myhsok; Florian Holsboer; Katharina Domschke

doi:10.1016/j.euroneuro.2009.08.006

HTR2A gene variation is involved in antidepressant treatment response

Eur Neuropsychopharmacol. 2010 Jan;20(1):65-8. doi: 10.1016/j.euroneuro.2009.08.006.

Authors

Susanne Lucae¹, Marcus Ising, Sonja Horstmann, Bernhard T Baune, Volker Arolt, Bertram Müller-Myhsok, Florian Holsboer, Katharina Domschke

Affiliation

¹ Max Planck Institute of Psychiatry, Munich, Germany.

PMID: 19758789
DOI: 10.1016/j.euroneuro.2009.08.006

Abstract

Two serotonin 2A receptor (HTR2A) SNPs recently reported to be associated with antidepressant treatment response in STARD (rs7997012; rs1928040) were analyzed for association with treatment response in two independent Caucasian samples of patients with a Major Depressive Episode. In the combined sample (n=637) SNP rs7997012 was significantly associated with remission after five weeks providing first replicative support for the initial finding, with, however, an inverse allelic association as compared to the STARD sample.

Publication types

Clinical Trial
Multicenter Study

MeSH terms

Adult
Analysis of Variance
Antidepressive Agents / therapeutic use*
Depressive Disorder, Major / drug therapy*
Depressive Disorder, Major / genetics*
Female
Gene Frequency
Genetic Predisposition to Disease*
Genome-Wide Association Study
Genotype
Humans
Male
Middle Aged
Pharmacogenetics*
Polymorphism, Single Nucleotide / genetics*
Psychiatric Status Rating Scales
Receptor, Serotonin, 5-HT2A / genetics

Substances

Antidepressive Agents
Receptor, Serotonin, 5-HT2A